Answers are grounded in this paper and cite their sources.
Bevacizumab has an extremely weak interaction with mVEGF-A, which fails to result in immunoneutralization as assessed by several bioassays.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: